Q3 2024 EPS Estimates for Balchem Co. Decreased by Analyst (NASDAQ:BCPC)

Balchem Co. (NASDAQ:BCPC) – Sidoti Csr reduced their Q3 2024 earnings per share estimates for Balchem in a note issued to investors on Monday, May 6th. Sidoti Csr analyst K. May now expects that the basic materials company will earn $1.04 per share for the quarter, down from their previous estimate of $1.06. The consensus estimate for Balchem’s current full-year earnings is $4.10 per share. Sidoti Csr also issued estimates for Balchem’s Q4 2024 earnings at $0.95 EPS, FY2024 earnings at $4.00 EPS, Q1 2025 earnings at $1.03 EPS, Q2 2025 earnings at $0.99 EPS, Q3 2025 earnings at $1.05 EPS and Q4 2025 earnings at $1.05 EPS.

BCPC has been the topic of a number of other research reports. StockNews.com lowered shares of Balchem from a “buy” rating to a “hold” rating in a research report on Thursday, April 25th. HC Wainwright increased their price target on Balchem from $167.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday.

Balchem Trading Up 1.4 %

BCPC stock opened at $155.48 on Wednesday. Balchem has a 52 week low of $110.74 and a 52 week high of $159.52. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.72 and a current ratio of 2.61. The company’s 50-day simple moving average is $151.00 and its 200 day simple moving average is $141.21. The company has a market capitalization of $5.04 billion, a PE ratio of 43.92, a price-to-earnings-growth ratio of 3.33 and a beta of 0.72.

Balchem (NASDAQ:BCPC) last issued its quarterly earnings data on Friday, February 16th. The basic materials company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.02. Balchem had a return on equity of 11.03% and a net margin of 12.35%. The firm had revenue of $228.70 million for the quarter, compared to analyst estimates of $234.66 million. During the same period in the prior year, the firm posted $0.66 EPS. The company’s revenue for the quarter was down 1.6% on a year-over-year basis.

Insider Buying and Selling

In related news, CEO Theodore L. Harris sold 34,350 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $154.29, for a total transaction of $5,299,861.50. Following the sale, the chief executive officer now owns 66,412 shares in the company, valued at approximately $10,246,707.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Theodore L. Harris sold 34,350 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $154.29, for a total transaction of $5,299,861.50. Following the completion of the transaction, the chief executive officer now owns 66,412 shares of the company’s stock, valued at approximately $10,246,707.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CAO William A. Backus sold 15,000 shares of the company’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $154.73, for a total value of $2,320,950.00. Following the sale, the chief accounting officer now owns 12,914 shares of the company’s stock, valued at $1,998,183.22. The disclosure for this sale can be found here. Insiders sold 76,630 shares of company stock valued at $11,843,249 over the last quarter. 1.77% of the stock is owned by company insiders.

Institutional Investors Weigh In On Balchem

Several hedge funds and other institutional investors have recently made changes to their positions in BCPC. Signaturefd LLC lifted its stake in Balchem by 123.0% in the 4th quarter. Signaturefd LLC now owns 165 shares of the basic materials company’s stock valued at $25,000 after purchasing an additional 91 shares during the last quarter. Principal Securities Inc. bought a new position in shares of Balchem in the 4th quarter valued at $28,000. Operose Advisors LLC acquired a new stake in shares of Balchem during the 3rd quarter valued at $31,000. GAMMA Investing LLC bought a new stake in Balchem during the 4th quarter worth $56,000. Finally, YHB Investment Advisors Inc. bought a new stake in Balchem during the 1st quarter worth $69,000. 87.91% of the stock is owned by institutional investors.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.